HeartBeam Inc. (NASDAQ: BEAT) reported positive results from its ALIGN-ACS pilot study, a 132-patient trial comparing its portable, cable-free electrocardiogram technology with standard 12-lead ECGs for assessing acute coronary syndrome. The data, presented at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego, matter because they suggest a patient-operated device could eventually support heart attack assessment outside traditional clinical settings, a capability that would extend the company's addressable market beyond arrhythmia detection.
The study found HeartBeam's system achieved 81.8% specificity versus 71.4% for standard ECGs, while sensitivity was comparable at 60.2% versus 63.0%. For ST-elevation myocardial infarction, sensitivity was 82.9% for HeartBeam and 83.8% for standard ECGs. Higher specificity implies fewer false positives, a critical factor when triaging patients remotely and avoiding unnecessary emergency interventions. All participants successfully recorded their own ECGs under clinical supervision without prior training, a result that underscores the device's usability and its potential for patient-driven monitoring.
Cardiologists interpreting HeartBeam recordings showed greater consistency than those reading standard ECGs, according to the study. That finding is important because inconsistent interpretation can lead to delayed or inappropriate care. The company plans to use the pilot data to inform a U.S. pivotal study expected to begin in the first quarter of 2027, with the goal of supporting a future Food and Drug Administration submission to expand the system's indication beyond arrhythmia assessment to include heart attack assessment.
HeartBeam's heart attack assessment technology has received FDA Breakthrough Device Designation, but the application remains investigational and is not currently FDA-cleared for heart attack assessment. The distinction matters for investors and clinicians: breakthrough designation can expedite review but does not authorize marketing. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software was cleared in December 2025. Details on the intended use of the technology are available through the company's cleared indications for use.
The ALIGN-ACS results carry implications for the broader cardiac monitoring market, where speed and accessibility can influence outcomes. HeartBeam describes its platform as the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG. If the pivotal trial confirms the pilot findings, the technology could give physicians a tool to identify cardiac trends and acute conditions outside a medical facility, redefining how heart health is managed.
For a company with more than 20 issued patents related to technology enablement, the pilot data provide a clinical rationale for the planned pivotal study. The full press release is available at https://ibn.fm/8QTjB, and ongoing updates relating to BEAT are posted in the company's newsroom at https://ibn.fm/BEAT. The announcement was syndicated through MissionIR, part of the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions.
